Annovis Bio is down -6.2%, or -58c to $8.70.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio Shares Surge on Positive Parkinson’s Study Data
- Annovis Bio’s buntanetap shows efficacy in Phase 3 Parkinson’s study
- Annovis Bio files provisional patent for manufacturing process of buntanetap
- Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
- Annovis Bio Files Patent for New Composition of Matter for Buntanetap